Strong operational quarter with record revenue and non-GAAP EPS, driven by 10th consecutive consensus beat and raised/updated guidance. The litigation charge creates headline noise but the underlying business momentum in contact lenses and fertility is intact. Watch for resolution of the strategic review at CooperSurgical and free cash flow trajectory toward $2.2B cumulative target over FY2026-2028.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 5 $67.34entry
- T+1 · 5mo ago −0.82%α −1.04% · $66.79
- T+5 · 5mo ago +0.80%α +0.23% · $67.88
- T+20 · 4mo ago +7.83%α +5.96% · $72.61
- T+60 · 3mo ago +3.87%α −0.13% · $69.94
Price Chart
How similar events traded
Executive Summary
CooperCompanies reported fiscal Q2 2026 results with revenue of $1.082B (+8% YoY) beating consensus of $1.05B, while GAAP EPS was -$0.40 due to a $271.6M litigation charge related to a fertility media recall. Non-GAAP EPS of $1.21 (+26% YoY) beat consensus of $1.10, and FY2026 guidance was updated with revenue of $4.285-4.321B and non-GAAP EPS of $4.58-4.66.
Key Financial Metrics
Key Facts
- Q2 revenue $1.082B (+8% YoY, +5% organic) vs $1.05B consensus, beat
- Non-GAAP diluted EPS $1.21 (+26% YoY) vs consensus $1.10, ~10% beat
- GAAP EPS -$0.40 due to $271.6M pre-tax litigation charge for fertility media recall
- FY2026 guidance: revenue $4.285-4.321B, organic growth 3.5-4.5%; non-GAAP EPS $4.58-$4.66
- CooperVision revenue $723.5M (+8% reported, +4% organic); CooperSurgical $358M (+8%, +6% organic)
- Record quarter for both revenue and non-GAAP EPS; tenth consecutive consensus beat
- Free cash flow $96.4M (operating $182.8M minus capex $86.4M)
Financial Impact
Non-GAAP EPS beat consensus by ~$0.11 (+10%). Revenue beat consensus by ~$32M (+3%). FY2026 guidance implies continued growth.
Risk Factors
- GAAP EPS deeply negative due to $271.6M litigation charge for fertility media recall, headline miss could cause short-term volatility
- CooperSurgical liability balance of $324.8M on balance sheet; additional unresolved claims may emerge
- Organic revenue growth of 4-5% is solid but unspectacular; macro headwinds or FX could weigh
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3307102 |
Track record
10 reports on COO
1 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +4.79% at T+20 after the Sep 17, 2026 report. 1 of 5 went positive at some point.
Filters
- Oct 27, 202620d ago 8-K Bearish 6/10 Entry $59.41 Now $61.88 −4.16% settles Nov 25
- Oct 15, 20264w ago Institutional Cluster Bearish 4/10 Entry $57.40 to $62.93 Now $61.88 −7.80% ▼ −9.63% −11.05% vs SPY
- Sep 17, 20268w ago Insider Cluster Bullish 4/10 Entry $55.29 to $57.94 Now $61.88 +11.92% ▲ +4.79% +4.59% vs SPY
- Sep 15, 20268w ago Insider Cluster Neutral 2/10 Entry $54.61 to $54.88 Now $61.88 +13.31% ▲ +0.49% −1.57% vs SPY
- Sep 9, 20269w ago Press Release Mixed 6/10 Entry $54.17 to $54.30 Now $61.88 +14.23% ▲ +0.24% −1.88% vs SPY
- Jun 4, 202623w ago 8-K Mixed 6/10 No price data
- Jun 4, 202623w ago Press Release Bullish 6/10 Viewing Entry $67.34 to $72.61 Now $61.88 −8.11% ▲ +7.83% +5.96% vs SPY
- Mar 5, 202636w ago 8-K Bullish 8/10 Entry $76.36 to $70.15 Now $61.88 −18.97% ▼ −8.13% −6.09% vs SPY
- Mar 5, 202636w ago Press Release Bullish 8/10 Entry $76.36 to $70.15 Now $61.88 −18.97% ▼ −8.13% −6.09% vs SPY
- Feb 24, 202637w ago DEFA14A Neutral 2/10 Entry $83.38 to $71.35 Now $61.88 −25.79% ▼ −14.43% −9.19% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers